EMA Panel Backs Weekly Hormone for Child Growth Disorders
The European Medicines Agency's panel has recommended expanding the use of a weekly growth hormone treatment for children with specific growth disorders. This treatment, Sogroya, could significantly reduce the frequency of injections needed for affected children. The positive opinion follows clinical trials demonstrating its efficacy in improving height velocity in children born small for gestational age and those with Noonan syndrome.
- ▪Sogroya is a long-acting growth hormone derivative that allows for once-weekly administration instead of daily injections.
- ▪The EMA's recommendation is based on clinical evidence showing superior height velocity outcomes compared to daily growth hormone treatments.
- ▪Common side effects of Sogroya include headache, hypothyroidism, and reactions at the injection site.
Medscape files mainly under health. We currently carry 231 of its stories.
Story provenance
Source · retrieval · rights · ranking — open for full record
inspect →
Story provenance
Attribution is not the same as permission. This drawer separates discovery metadata, excerpts, WeSearch-generated summaries, reuse status, and whether the publisher receives the visit. Nothing here claims a legal grant the publisher has not made.
Record
| Original publisher | Medscape |
| Canonical URL | https://www.medscape.com/viewarticle/ema-panel-backs-weekly-hormone-child-growth-disorders-2026a1000hb8?src=rss |
| Publication time | Tue, 26 May 2026 09:23:45 EDT |
| Retrieval time | 2026-05-26T13:37:49.521Z |
| Last seen | 2026-05-26T13:37:49.521Z |
| Headline source | Publisher (no WeSearch rewrite) |
| Excerpt source | publisher body |
| Excerpt method | First ~120 words (~800 chars) of extracted publisher body, fair-use limited. |
| Summary | WeSearch · cerebras-chat (WeSearch summarizer) |
| Summary source text | contentText |
| Citation coverage | Summary is a WeSearch-generated derivative; primary citation is the original publisher URL. |
| Cluster | hbh5MxI2TANC |
| Cluster logic | Grouped by semantic title/content similarity across sources within a rolling window. Same-publisher template collisions are excluded from coverage comparison. |
| Ranking reason | Story pages are not engagement-ranked. Hub feeds use recency, with optional source-diversified chronological ordering (cap consecutive stories per source). No personalized ranking. |
| Publisher visit | Yes — open original |
| Substitutes article? | No — link-out required for full text |
Rights status (four layers)
WeSearch handling by dimension
| Indexing | May the item be indexed (stored, ranked, made findable)? | Allowed |
| Snippet | May a short excerpt of the publisher's text be shown? | Allowed |
| AI summary | May WeSearch generate its own short summary of the article? | Limited |
| Retrieval / RAG | May the content be exposed for third-party retrieval-augmented generation? | Not asserted |
| Model training | May the content be used to train AI models? | Not asserted |
| Commercial reuse | May the content be reused commercially? | Not permitted |
Basis: Derived from the published RSS/Atom feed. Contact: [email protected]. Reviewed: 2026-07-24.
Opening excerpt (first ~120 words) tap to expand
Long-acting once-weekly growth hormone treatment has moved closer to expanded use in Europe for two new pediatric indications, potentially reducing injection frequency for children with specific growth disorders. The European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use has adopted a positive opinion recommending the expansion of approved indications for Sogroya (somapacitan, Novo Nordisk) for growth disturbances in children born small for gestational age (SGA) and for children with Noonan syndrome, in addition to its existing pediatric indication for growth hormone deficiency.Who Qualifies for Treatment For SGA patients, the indication covers children with current height standard deviation score (SDS) below -2.5 and parental adjusted height SDS below -1, who…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
